Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study of TXN10128, an Inhibitor of ENPP1 as Monotherapy and Combination Therapy With Irinotecan or Paclitaxel in Locally Advanced or Metastatic Solid Tumors

NCT05978492 is registered in ClinicalTrials.gov with Txinno Bioscience Inc. as lead sponsor.

NCT NCT05978492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05978492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study of TXN10128, an Inhibitor of ENPP1 as Monotherapy and Combination Therapy With Irinotecan or Paclitaxel in Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Txinno Bioscience Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 27, 2023
Completion date
June 30, 2026
Enrollment
96 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced (unresectable) or metastatic solid tumors